capecitabine has been researched along with Carcinoma, Basal Cell, Pigmented in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J; Nijhawan, RI; Schauder, DM | 1 |
| Konda, S; O'Bryan, KW; Patel, VA; Ratner, D | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Ahmed, RL; Dudek, A; Endrizzi, B; Lee, P; Ray, T | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
2 review(s) available for capecitabine and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review.
Topics: Breast Neoplasms; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Decision-Making; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Incidence; Keratosis, Actinic; Off-Label Use; Organ Transplantation; Patient Selection; Risk Assessment; Risk Factors; Skin Neoplasms; Transplant Recipients | 2020 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
3 other study(ies) available for capecitabine and Carcinoma, Basal Cell, Pigmented
| Article | Year |
|---|---|
Fibrohistiocytic tumors in a lung transplant patient taking oral capecitabine for nonmelanoma skin cancer chemoprevention.
Topics: Acitretin; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Deoxycytidine; Fatal Outcome; Fluorouracil; Graft vs Host Disease; Head and Neck Neoplasms; Histiocytoma, Malignant Fibrous; Humans; Keratolytic Agents; Lung Transplantation; Male; Skin Neoplasms | 2014 |
Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Basal Cell; Child; Child, Preschool; Deoxycytidine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Neoplasms, Squamous Cell; Organ Transplantation; Skin Neoplasms; Tumor Burden; Young Adult | 2013 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |